

Aralez Pharmaceuticals Inc.  
Form 8-K  
March 13, 2018

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **March 13, 2018**

---

**ARALEZ PHARMACEUTICALS INC.**

(Exact name of registrant as specified in its charter)

---

**British Columbia, Canada**  
(State or other jurisdiction of  
incorporation)

**001-37691**  
(Commission File Number)

**98-1283375**  
(IRS Employer Identification No.)

**7100 West Credit Avenue, Suite 101, Mississauga,**  
**Ontario, Canada**

**L5N 0E4**

Edgar Filing: Aralez Pharmaceuticals Inc. - Form 8-K

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code: **(905) 876-1118**

**Not Applicable**

(Former name or former address, if changed since last report.)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

**Item 2.02. Results of Operations and Financial Condition.**

On March 13, 2018, Aralez Pharmaceuticals Inc., a company formed under the laws of the Province of British Columbia, Canada (the Company), issued a press release announcing its results of operations for the quarter and full-year ended December 31, 2017. The full text of such press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.

**Item 7.01. Regulation FD Disclosures.**

As previously announced, the Company will conduct a conference call today, Tuesday, March 13, 2018 at 8:30 a.m. ET, to discuss its 2017 fourth quarter and full-year financial results and recent highlights. The presentation slides to be used during the call will be available on the Investors section of the Company's website (<http://www.aralez.com>) under the Presentations & Webcasts tab beginning at 8:30 a.m. ET on Tuesday, March 13, 2018. A question and answer session will follow the presentation. The conference call and the presentation slides will be simultaneously webcast on the Investors section of the Company's website under the Presentations & Webcasts tab beginning at 8:30 a.m. ET on Tuesday, March 13, 2018, and will remain available for future review for two weeks after the event. The information contained in, or that can be accessed through the Company's website, is not a part of this filing.

**Item 9.01. Financial Statements and Exhibits**

(d) List of Exhibits

<b>EXHIBIT NO.</b>	<b>DESCRIPTION</b>
99.1	Press Release, dated March 13, 2018, issued by Aralez Pharmaceuticals Inc.

EXHIBIT INDEX

<b>EXHIBIT NO.</b>	<b>DESCRIPTION</b>
99.1	<u>Press Release, dated March 13, 2018, issued by Aralez Pharmaceuticals Inc.</u>

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 13, 2018

**ARALEZ PHARMACEUTICALS INC.**

By:

*/s/ Eric L. Trachtenberg*  
Eric L. Trachtenberg  
General Counsel, Chief Compliance Officer and  
Corporate Secretary